Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: Distinct kinetics of interleukin-6 and -18 levels

Hiroyuki Wakiguchi, Shunji Hasegawa, Reiji Hirano, Hidenobu Kaneyasu, Midori Wakabayashi-Takahara, Shouichi Ohga

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Macrophage activation syndrome (MAS) is the secondary hemophagocytic lymphohistiocytosis associated with rheumatic diseases. Recently, the different cytokine profiles between systemic juvenile idiopathic arthritis (sJIA)-associated MAS (sJIA-MAS) and juvenile systemic lupus erythematosus (JSLE)-associated MAS (JSLE-MAS) were reported. However, there is little information about juvenile dermatomyositis (JDM)-associated MAS (JDM-MAS). Case presentation: A 4-year-old girl with JDM was hospitalized because of fever, erythema, hepatosplenomegaly, cytopenia, liver dysfunction and coagulopathy. Bone marrow aspiration revealed appreciable numbers of activated and hemophagocytosing macrophages. She was diagnosed as having JDM-MAS complicated with interstitial pneumonia (IP) based on the findings of the elevation of serum Krebs von den Lungen-6 (KL-6) levels and chest computed tomography findings. We analyzed circulating levels of interleukin (IL)-2,4,6,10,18, tumor necrosis factor-α and interferon-γ in the patient. Hypercytokinemia occurred at the diagnosis of MAS and IP, showing with the prominent elevations of IL-6 and IL-18 levels. The cytokine profiles were distinct from those reported in patients with sJIA-MAS or JSLE-MAS. High-dose corticosteroid and cyclosporine therapy led to a drastic improvement of MAS with decreased IL-6 levels. Subsequent cyclophosphamide therapy successfully controlled IP, paralleled with the declining pattern of IL-18 and KL-6 levels. Conclusion: This is the first report to describe a successful treatment and the cytokine profile of JDM-MAS and IP. Serum IL-6 and IL-18 levels may be useful for predicting the disease activity of JDM-MAS and IP, respectively.

Original languageEnglish
Article number49
JournalPediatric Rheumatology
Volume13
Issue number1
DOIs
Publication statusPublished - Nov 18 2015

Fingerprint

Macrophage Activation Syndrome
Interleukin-18
Interstitial Lung Diseases
Interleukin-6
Juvenile Arthritis
Cytokines
Systemic Lupus Erythematosus
Juvenile dermatomyositis
Hemophagocytic Lymphohistiocytosis
Erythema
Rheumatic Diseases
Serum
Interleukin-4
Cyclophosphamide
Interferons
Cyclosporine
Interleukin-2

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Rheumatology
  • Immunology and Allergy

Cite this

Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia : Distinct kinetics of interleukin-6 and -18 levels. / Wakiguchi, Hiroyuki; Hasegawa, Shunji; Hirano, Reiji; Kaneyasu, Hidenobu; Wakabayashi-Takahara, Midori; Ohga, Shouichi.

In: Pediatric Rheumatology, Vol. 13, No. 1, 49, 18.11.2015.

Research output: Contribution to journalArticle

Wakiguchi, Hiroyuki ; Hasegawa, Shunji ; Hirano, Reiji ; Kaneyasu, Hidenobu ; Wakabayashi-Takahara, Midori ; Ohga, Shouichi. / Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia : Distinct kinetics of interleukin-6 and -18 levels. In: Pediatric Rheumatology. 2015 ; Vol. 13, No. 1.
@article{f5d4958ff8c84890a14ee0780c254175,
title = "Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: Distinct kinetics of interleukin-6 and -18 levels",
abstract = "Background: Macrophage activation syndrome (MAS) is the secondary hemophagocytic lymphohistiocytosis associated with rheumatic diseases. Recently, the different cytokine profiles between systemic juvenile idiopathic arthritis (sJIA)-associated MAS (sJIA-MAS) and juvenile systemic lupus erythematosus (JSLE)-associated MAS (JSLE-MAS) were reported. However, there is little information about juvenile dermatomyositis (JDM)-associated MAS (JDM-MAS). Case presentation: A 4-year-old girl with JDM was hospitalized because of fever, erythema, hepatosplenomegaly, cytopenia, liver dysfunction and coagulopathy. Bone marrow aspiration revealed appreciable numbers of activated and hemophagocytosing macrophages. She was diagnosed as having JDM-MAS complicated with interstitial pneumonia (IP) based on the findings of the elevation of serum Krebs von den Lungen-6 (KL-6) levels and chest computed tomography findings. We analyzed circulating levels of interleukin (IL)-2,4,6,10,18, tumor necrosis factor-α and interferon-γ in the patient. Hypercytokinemia occurred at the diagnosis of MAS and IP, showing with the prominent elevations of IL-6 and IL-18 levels. The cytokine profiles were distinct from those reported in patients with sJIA-MAS or JSLE-MAS. High-dose corticosteroid and cyclosporine therapy led to a drastic improvement of MAS with decreased IL-6 levels. Subsequent cyclophosphamide therapy successfully controlled IP, paralleled with the declining pattern of IL-18 and KL-6 levels. Conclusion: This is the first report to describe a successful treatment and the cytokine profile of JDM-MAS and IP. Serum IL-6 and IL-18 levels may be useful for predicting the disease activity of JDM-MAS and IP, respectively.",
author = "Hiroyuki Wakiguchi and Shunji Hasegawa and Reiji Hirano and Hidenobu Kaneyasu and Midori Wakabayashi-Takahara and Shouichi Ohga",
year = "2015",
month = "11",
day = "18",
doi = "10.1186/s12969-015-0048-2",
language = "English",
volume = "13",
journal = "Pediatric Rheumatology",
issn = "1546-0096",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia

T2 - Distinct kinetics of interleukin-6 and -18 levels

AU - Wakiguchi, Hiroyuki

AU - Hasegawa, Shunji

AU - Hirano, Reiji

AU - Kaneyasu, Hidenobu

AU - Wakabayashi-Takahara, Midori

AU - Ohga, Shouichi

PY - 2015/11/18

Y1 - 2015/11/18

N2 - Background: Macrophage activation syndrome (MAS) is the secondary hemophagocytic lymphohistiocytosis associated with rheumatic diseases. Recently, the different cytokine profiles between systemic juvenile idiopathic arthritis (sJIA)-associated MAS (sJIA-MAS) and juvenile systemic lupus erythematosus (JSLE)-associated MAS (JSLE-MAS) were reported. However, there is little information about juvenile dermatomyositis (JDM)-associated MAS (JDM-MAS). Case presentation: A 4-year-old girl with JDM was hospitalized because of fever, erythema, hepatosplenomegaly, cytopenia, liver dysfunction and coagulopathy. Bone marrow aspiration revealed appreciable numbers of activated and hemophagocytosing macrophages. She was diagnosed as having JDM-MAS complicated with interstitial pneumonia (IP) based on the findings of the elevation of serum Krebs von den Lungen-6 (KL-6) levels and chest computed tomography findings. We analyzed circulating levels of interleukin (IL)-2,4,6,10,18, tumor necrosis factor-α and interferon-γ in the patient. Hypercytokinemia occurred at the diagnosis of MAS and IP, showing with the prominent elevations of IL-6 and IL-18 levels. The cytokine profiles were distinct from those reported in patients with sJIA-MAS or JSLE-MAS. High-dose corticosteroid and cyclosporine therapy led to a drastic improvement of MAS with decreased IL-6 levels. Subsequent cyclophosphamide therapy successfully controlled IP, paralleled with the declining pattern of IL-18 and KL-6 levels. Conclusion: This is the first report to describe a successful treatment and the cytokine profile of JDM-MAS and IP. Serum IL-6 and IL-18 levels may be useful for predicting the disease activity of JDM-MAS and IP, respectively.

AB - Background: Macrophage activation syndrome (MAS) is the secondary hemophagocytic lymphohistiocytosis associated with rheumatic diseases. Recently, the different cytokine profiles between systemic juvenile idiopathic arthritis (sJIA)-associated MAS (sJIA-MAS) and juvenile systemic lupus erythematosus (JSLE)-associated MAS (JSLE-MAS) were reported. However, there is little information about juvenile dermatomyositis (JDM)-associated MAS (JDM-MAS). Case presentation: A 4-year-old girl with JDM was hospitalized because of fever, erythema, hepatosplenomegaly, cytopenia, liver dysfunction and coagulopathy. Bone marrow aspiration revealed appreciable numbers of activated and hemophagocytosing macrophages. She was diagnosed as having JDM-MAS complicated with interstitial pneumonia (IP) based on the findings of the elevation of serum Krebs von den Lungen-6 (KL-6) levels and chest computed tomography findings. We analyzed circulating levels of interleukin (IL)-2,4,6,10,18, tumor necrosis factor-α and interferon-γ in the patient. Hypercytokinemia occurred at the diagnosis of MAS and IP, showing with the prominent elevations of IL-6 and IL-18 levels. The cytokine profiles were distinct from those reported in patients with sJIA-MAS or JSLE-MAS. High-dose corticosteroid and cyclosporine therapy led to a drastic improvement of MAS with decreased IL-6 levels. Subsequent cyclophosphamide therapy successfully controlled IP, paralleled with the declining pattern of IL-18 and KL-6 levels. Conclusion: This is the first report to describe a successful treatment and the cytokine profile of JDM-MAS and IP. Serum IL-6 and IL-18 levels may be useful for predicting the disease activity of JDM-MAS and IP, respectively.

UR - http://www.scopus.com/inward/record.url?scp=84960367688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960367688&partnerID=8YFLogxK

U2 - 10.1186/s12969-015-0048-2

DO - 10.1186/s12969-015-0048-2

M3 - Article

C2 - 26581448

AN - SCOPUS:84960367688

VL - 13

JO - Pediatric Rheumatology

JF - Pediatric Rheumatology

SN - 1546-0096

IS - 1

M1 - 49

ER -